Pharmacogenetics - genomics and personalized psychiatry

European Psychiatry

Volumn 25, Issue 5, 2010, Pages 291-293

  Moller H J ^a   Rujescu, D ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Pharmacogenetics; Pharmacogenomics; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ESCITALOPRAM; GLUCOCORTICOID RECEPTOR; NEUROLEPTIC AGENT; NORADRENALIN TRANSPORTER; NORTRIPTYLINE; PSYCHOTROPIC AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 3A RECEPTOR; SEROTONIN 3B RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 2;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MENTAL DISEASE; PATIENT COMPLIANCE; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHIATRY; UNSPECIFIED SIDE EFFECT; GENETICS; GENOMICS; PERSONALIZED MEDICINE;

GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHIATRY;

EID: 77953958070     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2009.12.015     Document Type: Article

References (20)

1. Bandelow B., Zohar J., Hollander E., Kasper S., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002, 3:171-199.
2. Bandelow B., Zohar J., Hollander E., Kasper S., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008, 9:248-312.
3. Bauer M., Whybrow P.C., Angst J., Versiani M., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002, 3:5-43.
4. Bauer M., Whybrow P.C., Angst J., Versiani M., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorder, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorder and subtreshold depressions. World J Biol Psychiatry 2002, 3:69-86.
5. Bauer M., Bschor T., Pfennig A., Whybrow P.C., Angst J., Versiani M., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007, 8:67-104.
6. Cook E.H., Scherer S.W. Copy-number variations associated with neuropsychiatric conditions. Nature 2008, 455:919-923.
7. Drago A., De Ronchi D., Serretti A. Pharmacogenetics of antidepressant response: an update. Hum Genomics 2009, 3:257-274.
8. Glessner J.T., Wang K., Cai G., Korvatska O., Kim C.E., Wood S., et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009, 459:569-573.
9. Grunze H., Kasper S., Goodwin G., Bowden C., Baldwin D., Licht R., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders, part I: Treatment of bipolar depression. World J Biol Psychiatry 2002, 3:115-124.
10. Grunze H., Kasper S., Goodwin G., Bowden C., Baldwin D., Licht R., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders, part II: Treatment of mania. World J Biol Psychiatry 2003, 4:5-13.
11. Grunze H., Kasper S., Goodwin G., Bowden C., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: Maintenance treatment. World J Biol Psychiatry 2004, 5:120-135.
12. Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Moller H.J., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009, 10:85-116.
13. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2008, 10.1038/mp.2008.116.
14. Levy D., Ehret G.B., Rice K., Verwoert G.C., Launer L.J., Dehghan A., et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41:677-687.
15. Norton N., Owen M.J. HTR2A: association and expression studies in neuropsychiatric genetics. Ann Med 2005, 37:121-129.
16. A framework for interpreting genome-wide association studies of psychiatric disorders. Mol Psychiatry. 2009, 14:10-17. Psychiatric GWAS Consortium Steering Committee.
17. Savitz J., Lucki I., Drevets W.C. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol. 2009, 88:17-31.
18. Serretti A., Kato M., De Ronchi D., Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007, 12:247-257.
19. Serretti A., Drago A., De Ronchi D. HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem 2007, 14:2053-2069.
20. Uher R., Huezo-Diaz P., Perroud N., Smith R., Rietschel M., Mors O., et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009, 9:225-233.